Drug Safety Developments

First trials over Xarelto injuries set for early 2017

Quoted from http://www.reuters.com/article/2015/09/21/products-xarelto-bellwether-idUSL1N11R2HC20150921

First trials over Xarelto injuries set for early 2017

By Jessica Dye

September 21, 2015

A federal judge in Louisiana has set dates for the first bellwether trials in consolidated litigation against a Johnson & Johnson subsidiary and Bayer AG over injuries allegedly caused by the blood-thinning drug Xarelto.

In an order Friday, U.S. District Judge Eldon Fallon in the Eastern District of Louisiana said the first Xarelto trial would take place in that court Feb. 6, 2017. A second bellwether trial will also be held in the Eastern District of Louisiana starting on March 13, 2017, and two more trials have been scheduled, respectively, to take place in Mississippi on April 24, 2017, and May 30, 2017 in Texas.

[Article continues at original source]

Related articles

Will There Be Another Drug Label Change For YAZ And Other Drospirenone (DRSP) Birth Control Pills, As FDA Required For Ortho Evra Years Ago

Onglyza Update: FDA May Require A New Warning About Possible Increased Risk Of Heart Failure For Diabetes Drugs Onglyza Or Kombiglyze XR

Takeda gets enough takers to complete $2.3B Actos settlement

Quoted from http://www.fiercepharma.com/story/takeda-gets-enough-takers-complete-23b-actos-settlement/2015-09-14

Takeda gets enough takers to complete $2.3B Actos settlement

Drugmaker agrees to kick in another $100M if enough claims pan out legit

September 14, 2015 | By Eric Palmer

A month ago it appeared like Takeda might not get enough takers to move forward with its sweeping $2.3 billion offer to settle thousands of claims over the cancer risks of diabetes drug Actos. But over the weekend, the Japanese drugmaker said it had raised the offer by $100 million if certain conditions are hit and now has enough on board to trigger the $2.3 billion settlement.

The company said it has 96% of the claimants signed up, and in the process has settled 7 of the 9 cases that have already gone to trial as well as many of the estimated 8,000 cases pending in state and federal courts. If 97% of the claims match up with the settlement criteria, Takeda said has agreed to cough up $2.4 billion.

The drugmaker said in a statement, that it continues to stand behind its product but that the payout allows it to focus on its future, while reducing "the uncertainties of complex litigation."

[Article continues at original source]

Related articles

Will There Be Another Drug Label Change For YAZ And Other Drospirenone (DRSP) Birth Control Pills, As FDA Required For Ortho Evra Years Ago

Onglyza Update: FDA May Require A New Warning About Possible Increased Risk Of Heart Failure For Diabetes Drugs Onglyza Or Kombiglyze XR

Zofran MDL For Lawsuits Filed In Federal Court Has Been Requested By Defendant Drug Company GlaxoSmithKline